Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Pharmacol. 2014 Mar;171(6):1347-60. doi: 10.1111/bph.12492.

The influence of cannabinoids on generic traits of neurodegeneration.

Author information

  • 1Trinity College Institute of Neuroscience, Department of Physiology, School of Medicine, University of Dublin, Trinity College, Dublin 2, Ireland.

Abstract

In an increasingly ageing population, the incidence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease are rising. While the aetiologies of these disorders are different, a number of common mechanisms that underlie their neurodegenerative components have been elucidated; namely neuroinflammation, excitotoxicity, mitochondrial dysfunction and reduced trophic support. Current therapies focus on treatment of the symptoms and attempt to delay the progression of these diseases but there is currently no cure. Modulation of the endogenous cannabinoid system is emerging as a potentially viable option in the treatment of neurodegeneration. Endocannabinoid signalling has been found to be altered in many neurodegenerative disorders. To this end, pharmacological manipulation of the endogenous cannabinoid system, as well as application of phytocannabinoids and synthetic cannabinoids have been investigated. Signalling from the CB1 and CB2 receptors are known to be involved in the regulation of Ca(2+) homeostasis, mitochondrial function, trophic support and inflammatory status, respectively, while other receptors gated by cannabinoids such as PPARγ, are gaining interest in their anti-inflammatory properties. Through multiple lines of evidence, this evolutionarily conserved neurosignalling system has shown neuroprotective capabilities and is therefore a potential target for neurodegenerative disorders. This review details the mechanisms of neurodegeneration and highlights the beneficial effects of cannabinoid treatment.

LINKED ARTICLES:

This article is part of a themed section on Cannabinoids 2013. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-6.

© 2013 The British Pharmacological Society.

KEYWORDS:

Alzheimer's disease; Huntington's disease; Parkinson's disease; cannabinoids; excitotoxicity; mitochondrial dysfunction; neurodegeneration; neurogenesis; neuroinflammation

PMID:
24172185
[PubMed - indexed for MEDLINE]
PMCID:
PMC3954477
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk